Clinical Scorecard: Long-term Abstinence Achieved in Severe Ketamine Use Disorder After Ibogaine Intervention: A Case Study

At a Glance

Key Highlights

• Patient achieved immediate cessation of cravings for all substances post-ibogaine treatment.
• Sustained abstinence documented over 17 months with serial toxicology and psychometric assessments.
• Significant improvements in depression and quality of life metrics were observed.
• Ibogaine's unique pharmacology may facilitate long-term behavioral changes.
• First longitudinally documented case of sustained abstinence in severe ketamine use disorder following ibogaine treatment.

Guideline-Based Recommendations

Diagnosis

• Assessment of substance use disorders, including ketamine dependence and comorbid psychiatric conditions.

Management

• Consider ibogaine-assisted treatment within a structured program for severe ketamine use disorder.

Monitoring & Follow-up

• Continuous medical and ECG monitoring during ibogaine administration.

Risks

• Potential safety risks associated with ibogaine, including QT-interval prolongation and neurotoxicity.

Patient & Prescribing Data

30-year-old male with a five-year history of severe polysubstance dependence.

Ibogaine treatment involved an 800 mg flood dose followed by booster doses, leading to significant clinical improvements.

Clinical Best Practices

• Implement structured treatment programs for substance use disorders.
• Utilize continuous monitoring during ibogaine administration to mitigate risks.
• Incorporate psychosocial support alongside pharmacological interventions.

Related Resources & Content

• Ibogaine Pharmacology and Safety
• Substance Use Disorder Treatment Strategies